Celgene (NASDAQ:CELG) reported fourth quarter results on Thursday morning, beating profit estimates but missing sales estimates slightly. The company remains on growth track and looks inexpensive.
Celgene trades at $111 right now, down 2% today and 12% below the 52 week high.
Total revenues for the quarter came in at $2.98 billion, up 17% year on year -- a deceleration from the 22% growth rate for the whole year, but that was likely just a small hiccup for the company.
The key growth driver for Celgene's steadily rising revenues are higher volumes, based on higher patient counts and increasing average duration, which is a huge positive. Unlike other companies, Celgene does not generate growth by excessively hiking its prices, but rather by bringing its drugs to more patients, which makes Celgene less vulnerable to political pressure.
